Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4271-4279

  Zhou, Qingyu ^a   Guo, Ping ^a   Kruh, Gary D ^b   Vicini, Paolo ^c   Wang, Xiaomin ^a   Gallo, James M ^a  

^a TEMPLE UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CEREBROSPINAL FLUID; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISPOSITION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; DACARBAZINE; HUMANS; MODELS, ANIMAL; RATS;

EID: 34547132048     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0658     Document Type: Article

References (34)

1. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer 1992;65:287-91.
2. Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 2006;6:1187-204.
3. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000;17:1284-9.
4. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999;5:309-17.
5. Ma J, Fei ZL, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis 1998;16:559-68.
6. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001;61:5491-8.
7. Paxinos G, Watson C. The rat brain in stereotaxic coordinates 3rd ed. Amsterdam: Elsevier Academic Press; 1997.
8. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
9. Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J 2005;7:E659-67.
10. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 2007;321:265-75.
11. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998;47:484-92.
12. SAAM II and PopKinetics, version 1.0b. Seattle (WA): University of Washington; 1999-2001.
13. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-36.
14. Kawakami J, Yamamoto K, Sawada Y, Iga T. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J Pharmacokinet Biopharm 1994;22:207-27.
15. Davies B, Morris T. Physiological parameters in laboratory animals and humans Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
16. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003;228:523-32.
17. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55.
18. Collins JM, Dedrick RL. Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 1983;245:R303-10.
19. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994;33:9045-51.
20. Fross RD, Warnke PC, Groothuis DR. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research. J Neurooncol 1991;11:185-97.
21. Uematsu H, Maeda M. Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006;16:180-6.
22. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999;58:312-28.
23. Gallo JM, Vicini P, Orlansky A, et al. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res 2004;10:8048-58.
24. Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003;63:5114-7.
25. Lin JH, Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-49.
26. Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31.
27. Keep RF, Jones HC. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries, and ventricular ependyma in the rat. Brain Res Dev Brain Res 1990;56:47-53.
28. Speake T, Brown PD. Ion channels in epithelial cells of the choroid plexus isolated from the lateral ventricle of rat brain. Brain Res 2004;1005:60-6.
29. Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 2006;24:1228-35.
30. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983;245:R768-75.
31. Holleran JL, Parise RA, Joseph E, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005;11:3862-8.
32. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm 1995;23:217-29.
33. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 1986;75:1028-40.
34. Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004;32:603-11.